Press Releases

Press Release: Sanofi’s Consumer Healthcare unit launches the Shared Care Collective, an advisory group working to advance sustainability

Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease

Media Update: Sanofi completes closing for potential first-in-class vaccine against extraintestinal pathogenic E.coli (ExPEC)

Press Release: Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results

Press Release: Sanofi Enters Next Chapter of Play to Win Strategy

Press Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)

Media Update: Sanofi and Regeneron provide update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria

Press Release: Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio

Press Release: TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously published in The NEJM

Press Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis

Media Update: New data at WMS 2023 reaffirm long-term efficacy of Nexviazyme® (avalglucosidase alfa) for the treatment of Pompe disease

Press Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment

Press Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli

Media Update: Sanofi presents new data from robust MS clinical pipeline exploring multiple approaches to address important unmet patient needs

Media Update: Sanofi completes acquisition of Qunol®

Press Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review

Press Release: Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A

Press Release: Availability of the Q3 2023 Memorandum for modelling purposes

Press Release: Sanofi supporting vulnerable communities as part of commitment to social impact and fight against climate change

Media Update: New data at ERS showed Xenpozyme® (olipudase alfa) improved respiratory functions in adults with ASMD